Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.
Despite technical glitches, the federal "Open Payments" database -- which tracks pharmaceutical company contributions to doctors and teaching hospitals -- remains on track for its scheduled Sept. 30 launch, the Centers for Medicare and Medicaid Services confirmed.
It was mandated by a sunshine act included in the federal health law seeking to ease concerns that pharmaceutical interests could wield excessive influence over health providers. The database includes payments for research, gifts, meals, or speaker fees. Consumer advocates have long called for the public display of such information, arguing that it is key to ensuring doctors don't prescribe certain drugs out of financial incentives or loyalty.
As planned, the initial site will contain 5 months' worth of payment information, spanning August 2013 through December 2013. But after a series of fits and starts, about one-third of the payment information for that period won't be included because of questions that recently surfaced about its accuracy.
Link to the article on medpage TODAY: http://bit.ly/1qPN9O1
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More